. .
:
..
..
..
.
- .
, ..
,
.
,
, ,
.
,
.
,
,
.
,
- ,
.
,
,
, -
, .
p-
.
,
,
,
. .
,
,
. ,
,
PubMed eLibrary
2023 .,
,
. : ,
, , pH-, .
: ..,
.., .. :
. .
2024; 2 (27): 31-35. https://doi.org/10.51793/OS.2024.27.2.006
.
,
.
- ().
,
,
,
. ,
1 ,
, [1].
,
.
,
IV ,
,
(),
,
,
.
3 ,
6
[2].
40%
- . ,
,
,
,
, ,
,
[3].
PubMed
2023 ., ,
,
,
. . 1
.
,
:
, ,
[4]. J.
Abdallah . [5] ,
45%
()
()
, 75%
.
[6]
pH-
86,15%, 46,9%
39,2% .
[4] ,
(),
,
,
, ,
.
, ,
:
,
2 [7].
,
,
[8].
A. Geeraerts . [9]
,
.
,
. A.
Caballero-Mateos . [10] ,
.
,
,
,
p- p-
( ).
,
,
,
[11].
,
,
,
,
[12].
, ,
/
[13].
,
.
, ,
,
[14].
,
,
,
. 24-
-, E. Marabotto
.,
,
[15].
Y. Ren . [16]
.
30
60
.
.
, ,
(PSPW)
.
pH-
(AET),
PSPW
[17].
. [18]
,
(MNBI)
. MNBI
3 5
10-
[7]. MNBI
,
( > 4). ,
,
.
R.A. Cassiani .
, , ,
,
.
, ,
[19].
.
.
, -,
,
[11].
Peptest ( ,
). .
,
.
,
[20].
.
,
.
, ,
[21].
. 2
,
[22].
,
,
.
- ,
, ,
, ,
,
[23]. V. Savarino ., ,
,
,
(),
.
,
3%
[24].
. ,
()
51 35
, 7
.
[25].
[8].
[26] ,
(
) .
,
.
,
.
,
,
.
-
,
[27].
,
[28].
E.D. Shah .
,
.
,
.
,
[29].
,
,
.
,
[30].
,
,
. , -
.
.
, ,
,
.
,
,
,
.
,
.
,
.
,
. :
. Contribution of authors: All authors
contributed equally to this work and writing of
the article at all stages. / References
- Feldman M., Friedman L., Brandt L.
Sleisenger and Fordtrans Gastrointestinal and
Liver Disease, 11 ed. Philadelphia: Elsevier,
2021.
- Rome IV Criteria. Appendix A: Rome IV
Diagnostic Criteria for FGIDs.
- Black C.J. et al. Functional
gastrointestinal disorders: advances in
understanding and management. The Lancet. 2020;
396 (10263): 1664-1674. DOI:
10.1016/S0140-6736(20)32115-2.
- Piza L.A., Cárdenas-Oña M., Vásquez-Ojeda
X., Rosas-Marcos E., et al. Functional Heartburn
and Esophageal Hypersensitivity Frequency in
Patients With Refractory Gastroesophageal Reflux
Symptoms: Using the Roma IV Consensus and a
Series of Diagnostic Procedures in Lima, Peru.
The American Journal of Gastroenterology. 2021;
116: 176. DOI:
10.14309/01.ajg.0000774064.71116.b3.
-
Abdallah J., George N., Yamasaki T., et al. Most
Patients With Gastroesophageal Reflux Disease
Who Failed Proton Pump Inhibitor Therapy Also
Have Functional Esophageal Disorders. Clinical
Gastroenterology and Hepatology. 2019; 17 (6):
1073-1080. DOI: 10.1016/j.cgh.2018.06.018.
- Piza-Palacios L., Cárdenas-Oña M.,
Vásquez-Ojeda X., Alurralde. Frequency of
functional esophageal disorders in patients with
refractory reflux symptoms in Lima, Peru. Revista de Gastroenterología del Perú. 2023; 43
(3): 242-250. DOI: 10.47892/rgp.2023.433.1498.
- Lee Yeong Yeh, Justin C.Y. Wu. Management of
Patients With Functional Heartburn.
Gastroenterology. 2018; 154 (8): 2018-2021. DOI:
10.1053/j.gastro.2018.04.030.
- Lazarescu A., Demers-Leblanc A., Kamal A.
Esophageal Hypersensitivity and Functional
Dyspepsia. The AFS Textbook of Foregut Disease.
Springer, Cham. 2023. DOI:
10.1007/978-3-031-19671-3_8.
- Geeraerts A., Guadagnoli L., Pauwels A., et
al. Psychological symptoms do not discriminate
between reflux phenotypes along the
organic-functional refractory GERD spectrum. Gut.
2023; 72: 1819-1827. DOI:
10.1136/gutjnl-2023-329673.
- Caballero-Mateos A.M., López-Hidalgo J.L.,
Torres-Parejo U., Hernández-González J.M. Risk
factors for functional dyspepsia, erosive and
non-erosive gastroesophageal reflux disease: A
cross-sectional study. Gastroenterología y
Hepatología. 2023; 46 (7): 542-552. DOI:
10.1016/j.gastrohep.2022.12.005.
- Helle K., Árok A.Z., Ollé G., Antal M.,
Rosztóczy A. Dental evaluation is helpful in the
differentiation of functional heartburn and
gastroesophageal reflux disease. World J
Gastroenterol. 2023; 29 (31): 4774-4782. DOI:
10.3748/wjg.v29.i31.4774.
- Gyawali C.P., Carlson D.A., Chen J.W., Patel
A., et al. ACG Clinical Guidelines: Clinical Use
of Esophageal Physiologic Testing. Am J
Gastroenterol. 2020; 115 (9): 1412-1428. DOI:
10.14309/ajg.0000000000000734.
- Gyawali C. Prakash, et al. Modern diagnosis
of GERD: the Lyon Consensus. Gut. 2018; 67 (7):
1351-1362. DOI: 10.1136/gutjnl-2017-314722.
- Zerbib F., Bredenoord A.J., Fass R.,
Kahrilas P.J., et al. ESNM/ANMS consensus paper:
Diagnosis and management of refractory
gastro-esophageal reflux disease.
Neurogastroenterology & Motility. 2021; 33:
4075. DOI: 10.1111/nmo.14075.
- Marabotto E., Savarino V., Ghisa M.,
Frazzoni M., et al. Advancements in the use of
24-hour impedance-pH monitoring for GERD
diagnosis. Current Opinion in Pharmacology.
2022; 65. DOI: 10.1016/j.coph.2022.102264.
- Ren Y., Guo X., Cai Y., Huo X., et al.
Difference in meal-related esophageal
intraluminal impedance change between
gastroesophageal reflux disease and functional
disorders. Scandinavian Journal of
Gastroenterology. 2023; 58 (5): 443-447. DOI:
10.1080/00365521.2022.2141073.
-
Ribolsi M, Frazzoni M, Marabotto E, et al. Novel
impedance-pH parameters are associated with
proton pump inhibitor response in patients with
inconclusive diagnosis of gastro-oesophageal
reflux disease according to Lyon Consensus.
Aliment Pharmacol Ther. 2021; 54: 412-418. DOI:
10.1111/apt.16481.
- Sararu R., Peagu R.,
Fierbinteanu-Braticevici C. The Role of Distal
Mean Nocturnal Baseline Impedance in
Differentiating GERD Phenotypes. Journal of
Gastrointestinal and Liver Diseases. 2023; 32
(3): 291-297. DOI: 10.15403/jgld-4669.
- Cassiani R.A., Dantas R.O. Oral And
Pharyngeal Transit In Functional Heartburn.
Arquivos De Gastroenterologia. 2020; 57 (2):
150-153. DOI: 10.1590/S0004-2803.202000000-28.
- Yadlapati R., Kaizer A., Greytak M., Ezekewe
E., et al. Diagnostic performance of salivary
pepsin for gastroesophageal reflux disease.
Diseases of the Esophagus. 2021; 34 (4): 117.
DOI: 10.1093/dote/doaa117.
- Gorgulu V., Ergun P., Kipcak S.,
Doganavsargil B., et al. Revisiting the Role of
Esophageal Mucosal Dilated Intercellular Spaces
in the Diagnosis and Pathophysiology of
Heartburn. J Neurogastroenterol Motil. 2023; 29
(4): 436-445. DOI: 10.5056/jnm22142.
- Yamasaki T., Fass R. Reflux Hypersensitivity:
A New Functional Esophageal Disorder. J
Neurogastroenterol Motil. 2017; 23 (4): 495-503.
DOI: 10.5056/jnm17097.
- Xiong N., Wei J., Ke M., Hong X., et al.
Illness Perception of Patients with Functional
Gastrointestinal Disorders. Front. Psychiatry.
Sec. Psychological Therapy and Psychosomatic.
2018; 9. DOI: 10.3389/fpsyt.2018.00122.
- Savarino V., Marabotto E., Zentilin P., De
Bortoli N., et al. How safe are heartburn
medications and who should use them? Expert
Opinion on Drug Safety. 2023; 22 (8): 643-652.
DOI: 10.1080/14740338.2023.2238592.
- Alkhowaiter S., Alshahrani A., Almarzouqi
H., et al. Feasibility, and barriers to use
escitalopram in functional gastrointestinal
disorders. Front Pharmacol. Sec. Drugs Outcomes
Research and Policies. 2023; 14. DOI:
10.3389/fphar.2023.1131354.
- Lee S., Lee H. Psychological Characteristics
and Quality of Life of Patients with Upper and
Lower Functional Gastrointestinal Disorders.
European Psychiatry. 2023; 66 (1): 401. DOI:
10.1192/j.eurpsy.2023.865.
- Law M., Pickering I., Bartlett E.,
Sebaratnam G., et al. Cognitive behavioural
therapy-based interventions for gastroduodenal
disorders of gut-brain interaction: A systematic
review. Journal of Psychosomatic Research. 2023;
175. DOI: 10.1016/j.jpsychores.2023.111516.
- Yadlapati R., Prakash Gyawali C., Pandolfino
J.E., Chang K., et al. AGA Clinical Practice
Update on the Personalized Approach to the
Evaluation and Management of GERD: Expert Review.
Clinical Gastroenterology and Hepatology. 2022;
20 (5): 984-994. DOI: 10.1016/j.cgh.2022.01.025.
- Shah E.D., Chan W.W., Jodorkovsky D., Lynch
K.L., et al. Optimizing the Management Algorithm
for Heartburn in General Gastroenterology:
Cost-Effectiveness and Cost-Minimization
Analysis. Clinical Gastroenterology and
Hepatology. 2023. DOI:
10.1016/j.cgh.2023.08.026.
- Fass R., Zerbib F., Gyawali C.P. AGA
Clinical Practice Update on Functional Heartburn:
Expert Review. Gastroenterology. 2020; 158 (8):
2286-2293. DOI: 10.1053/j.gastro.2020.01.034.
http://www.gastroscan.ru
| |
|  |
|
Спутники
РН
SpaceX
Роскосмос
NASA